Roche wins Japan approval for personalized cancer drug Rozlytrek

Published 18/06/2019 in Medicine

Roche wins Japan approval for personalized cancer drug Rozlytrek

ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients.

Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumors, across 10 different tumor types, including those with central nervous system metastases.

Print article

Leave a Reply

Please complete required fields